Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 42 recruiting now official registry

Anatomic Stage IV Breast Cancer AJCC v8 clinical trials

42 of 60 indexed Anatomic Stage IV Breast Cancer AJCC v8 trials are currently recruiting.

60 US clinical trials · 42 currently recruiting

Anatomic Stage IV Breast Cancer AJCC v8 is the subject of 60 registered US clinical trials on ClinicalTrials.gov, 42 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 47 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 16 of these trials.

The research picture

Anatomic Stage IV Breast Cancer AJCC v8 has 60 registered US clinical trials, 42 of them open to new participants right now, about 70% of the total.

42
recruiting participants now
70%
of trials open to enrollment
4
in Phase 3–4 (later-stage)
16
top sponsor: National Cancer Institute (NCI)
Phase 122Phase 225Phase 33Phase 41

Active & Recent Trials

60 total, page 1 of 2

RECRUITING Phase 2 2,900 participants

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

NCT05564377

RECRUITING 1,600 participants

National Cancer Institute "Cancer Moonshot Biobank"

National Cancer Institute (NCI)

NCT04314401

RECRUITING NA 739 participants

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

SWOG Cancer Research Network

NCT03723928

RECRUITING 700 participants

Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors

Roswell Park Cancer Institute

NCT04526587

RECRUITING NA 410 participants

Mobile Health for Adherence in Breast Cancer Patients

ECOG-ACRIN Cancer Research Group

NCT06112613

RECRUITING Phase 3 269 participants

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

NRG Oncology

NCT06500455

RECRUITING 230 participants

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Mayo Clinic

NCT04517838

RECRUITING Phase 1 132 participants

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Mayo Clinic

NCT05269381

RECRUITING Phase 3 115 participants

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

NRG Oncology

NCT06500481

RECRUITING Phase 1 100 participants

The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors

University of California, Davis

NCT05967533

RECRUITING Phase 2 75 participants

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

University of Michigan Rogel Cancer Center

NCT07158021

RECRUITING Phase 2 70 participants

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

National Cancer Institute (NCI)

NCT03606967

RECRUITING Phase 2 60 participants

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

University of Washington

NCT06179303

RECRUITING Phase 2 60 participants

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

M.D. Anderson Cancer Center

NCT04090567

RECRUITING Phase 1 57 participants

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

National Cancer Institute (NCI)

NCT05422794

RECRUITING Phase 1 54 participants

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

Mayo Clinic

NCT04521764

RECRUITING Phase 1 51 participants

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

NCT04704661

RECRUITING 50 participants

Living Well With Advanced Breast Cancer

Ohio State University Comprehensive Cancer Center

NCT07227038

RECRUITING Phase 2 50 participants

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

M.D. Anderson Cancer Center

NCT04771520

RECRUITING NA 45 participants

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy

Mayo Clinic

NCT06055881

RECRUITING Phase 1 45 participants

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

National Cancer Institute (NCI)

NCT05372640

RECRUITING Phase 2 43 participants

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

City of Hope Medical Center

NCT04305834

RECRUITING Phase 1 42 participants

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Margaret Gatti-Mays

NCT06026657

RECRUITING Phase 2 40 participants

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

University of Washington

NCT07112053

RECRUITING Phase 1 36 participants

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

National Cancer Institute (NCI)

NCT07137416

RECRUITING Phase 2 36 participants

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

National Cancer Institute (NCI)

NCT04550494

RECRUITING Phase 2 35 participants

Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer

City of Hope Medical Center

NCT06910761

RECRUITING Phase 2 35 participants

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

Mayo Clinic

NCT06525766

RECRUITING Phase 1 34 participants

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Yuan Yuan

NCT05318469

RECRUITING Phase 1 32 participants

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

National Cancer Institute (NCI)

NCT05673200

RECRUITING Phase 2 30 participants

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Roswell Park Cancer Institute

NCT06434064

RECRUITING Phase 1 25 participants

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Fred Hutchinson Cancer Center

NCT05098210

RECRUITING Phase 2 23 participants

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Roswell Park Cancer Institute

NCT04348747

RECRUITING Phase 2 22 participants

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

University of Washington

NCT06518057

RECRUITING Phase 1 22 participants

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

University of Washington

NCT06502691

RECRUITING Phase 1 20 participants

An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial

Mayo Clinic

NCT06999798

RECRUITING Phase 2 20 participants

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

University of Washington

NCT07078604

RECRUITING Phase 2 18 participants

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

City of Hope Medical Center

NCT06260033

RECRUITING Phase 1 18 participants

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Jonsson Comprehensive Cancer Center

NCT05319873

RECRUITING Phase 2 11 participants

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

City of Hope Medical Center

NCT06860815

RECRUITING Phase 4 10 participants

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

City of Hope Medical Center

NCT05376878

RECRUITING NA 5 participants

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer

Mayo Clinic

NCT05746325

ACTIVE NOT RECRUITING Phase 3 608 participants

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

National Cancer Institute (NCI)

NCT02115282

ACTIVE NOT RECRUITING NA 243 participants

A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer

Ohio State University Comprehensive Cancer Center

NCT05215769

ACTIVE NOT RECRUITING Phase 2 138 participants

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

ECOG-ACRIN Cancer Research Group

NCT04316117

ACTIVE NOT RECRUITING Phase 2 81 participants

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

National Cancer Institute (NCI)

NCT02849496

ACTIVE NOT RECRUITING Phase 2 70 participants

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

National Cancer Institute (NCI)

NCT04090398

ACTIVE NOT RECRUITING Phase 1 57 participants

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

National Cancer Institute (NCI)

NCT02453620

ACTIVE NOT RECRUITING Phase 2 44 participants

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

SWOG Cancer Research Network

NCT04647916

ACTIVE NOT RECRUITING Phase 2 30 participants

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

OHSU Knight Cancer Institute

NCT06630325

Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 22
Phase 2 25
Phase 3 3
Phase 4 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Anatomic Stage IV Breast Cancer AJCC v8 Trial Landscape

60 indexed Anatomic Stage IV Breast Cancer AJCC v8 studies · 42 recruiting (70%).

Phase mix: 4 late (III/IV) vs 47 early (I/II).

Top sponsor: National Cancer Institute (NCI) (16 trials), 9 others listed. 50 shown below, recruiting first.

How to read this condition's trial landscape

That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Anatomic Stage IV Breast Cancer AJCC v8?

PlainTrial tracks 60 US clinical trials for Anatomic Stage IV Breast Cancer AJCC v8, of which 42 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Anatomic Stage IV Breast Cancer AJCC v8?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.